Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach